aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.4987
+0.0014 (0.28%)
Sep 8, 2026, 11:13 AM EDT - Market open
aTyr Pharma Revenue
In the year 2025, aTyr Pharma had annual revenue of $190.00K, down -19.15%.
Revenue (ttm)
$190.00K
Revenue Growth
-19.15%
P/S Ratio
256.73
Revenue / Employee
$3,167
Employees
60
Market Cap
48.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 190.00K | -45.00K | -19.15% |
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | 422.00K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Werewolf Therapeutics | 21.00M |
| Veru Inc. | 16.89M |
| Immutep | 13.79M |
| Metagenomi Therapeutics | 13.56M |
| Seres Therapeutics | 1.88M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
ATYR News
- 6 days ago - aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewsWire
- 8 days ago - aTyr Pharma Proxy statement: Proxy filing - Filings
- 19 days ago - Ethos to Present at the Goldman Sachs Communacopia + Technology Conference - GlobeNewsWire
- 26 days ago - Ethos Signs Erin Andrews as Its Next Sports Partner in Growing Campaign to Make Life Insurance Accessible for Every Family - GlobeNewsWire
- 4 weeks ago - aTyr Pharma reports Q2 EPS (11c), consensus (13c) - TheFly
- 4 weeks ago - aTyr Pharma announces restructuring, will lay off roughly 60% of workforce - TheFly
- 4 weeks ago - aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - GlobeNewsWire
- 4 weeks ago - aTyr Pharma Quarterly report: Q2 2026 - Filings